1. 476ryburn
2. shinitsky
3. melsweet77
1.476ryburn 05/10/2018
Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
2.shinitsky 03/27/2018
Submits an IND application w/ the FDA to initiate a Phase 1/2, first in-human trial of KB103 to deliver a hu…
3.476ryburn 03/28/2018
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
4.476ryburn 03/13/2018
Krystal Biotech Reports 2017 Financial Results and Business Progress
5.shinitsky 04/19/2018
Krystal Biotech's KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW